Literature DB >> 25877292

Adherence to Mediterranean Diet Offers an Additive Protection Over the Use of Statin Therapy: Results from the ATTICA Study (2002-2012).

Demosthenes B Panagiotakos1, Ekavi N Georgousopoulou, Georgios A Georgiopoulos, Christos Pitsavos, Christina Chrysohoou, Ioannis Skoumas, Maria Ntertimani, Alexandros Laskaris, Lampros Papadimitriou, Dimitrios Tousoulis, Christodoulos Stefanadis.   

Abstract

BACKGROUND AND AIMS: The protective role of Mediterranean diet on cardiovascular disease (CVD) risk has been extensively discussed in the literature, but its incremental effect over the use of CVD risk reducing agents (such as hypolipidemic treatment) has rarely been evaluated.
METHODS: The ATTICA study was carried out in the Athens area during 2001-2002 and included 3042 participants free of CVD at baseline (49.8% men, aged 18-89 years). Adherence to Mediterranean diet was assessed using the MedDietScore (range 0-55) and statin use was recorded for all subjects. During 2011-2012, 2583 out of the 3042 baseline participants attended the 10-year follow-up of the ATTICA study (15% lost-to-follow-up) and CVD development was recorded.
RESULTS: Adherence to Mediterranean diet (highest tertile) decreased CVD risk by 29.3% (Hazard Ratio (HR): 0.707, 95% Confidence Intervals (CI): 0.537-0.831) as compared with the lowest tertile, independently of statin use. Patients with hyperlipidemia on a statin that adopted unhealthy dietary habits (lowest tertile) had 75% increased CVD risk than normolipidemic subjects with healthy dietary habits (HR=1.75, 95%CI: 1.33-2.29). The addition of Mediterranean diet tertiles in the multivariable model reclassified 46.7% of the participants to CVD risk categories.
CONCLUSION: Adherence to Mediterranean diet confers a considerable reduction in CVD risk, independently of gender, age, family history of CVD, diabetes mellitus, smoking status, hypertension and physical activity status. Therefore, CVD prevention strategies should involve the implementation of a Mediterranean diet in both the general population and patients on a statin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25877292     DOI: 10.2174/1570161113666150416124957

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  3 in total

1.  Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

Authors:  F Barkas; M Elisaf; C V Rizos; E Klouras; M S Kostapanos; E Liberopoulos
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

Review 2.  Lifestyle Modification in Secondary Prevention: Beyond Pharmacotherapy.

Authors:  Jenna Brinks; Amy Fowler; Barry A Franklin; Jassu Dulai
Journal:  Am J Lifestyle Med       Date:  2016-07-08

3.  Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach.

Authors:  Adelle M Gadowski; Natalie Nanayakkara; Stephane Heritier; Dianna J Magliano; Jonathan E Shaw; Andrea J Curtis; Sophia Zoungas; Alice J Owen
Journal:  Nutrients       Date:  2019-08-09       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.